 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Onconova Therapeutics, Inc. (NASDAQ:ONTX  Get Free Report) saw a significant increase in short interest in the month of November. As of November 15th, there was short interest totalling 85,500...

Onconova Therapeutics, Inc. (NASDAQ:ONTX) Short Interest Up 21.1% in November

NEWTOWN, Pa., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), ( Onconova , the Company ), a clinical-stage biopharmaceutical company focused on discovering and...

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference

Onconova Therapeutics, Inc. (NASDAQ:ONTX  Get Free Report) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.94 and traded as...

Onconova Therapeutics (NASDAQ:ONTX) Stock Price Crosses Below Two Hundred Day Moving Average of $0.94

Analysts at StockNews.com initiated coverage on shares of Onconova Therapeutics (NASDAQ:ONTX  Get Free Report) in a note issued to investors on Thursday. The brokerage set a sell&#8221...

Onconova Therapeutics (NASDAQ:ONTX) Receives New Coverage from Analysts at StockNews.com

Onconova Therapeutics, Inc. (ONTX) Q3 2023 Earnings Call Transcript...

Onconova Therapeutics, Inc. (ONTX) Q3 2023 Earnings Call Transcript

Narazaciclib progressing towards registrational studies; target engagement and acceptable safety profile support further dose escalation, affirming differentiated profile Update on the...

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

StockNews.com began coverage on shares of Onconova Therapeutics (NASDAQ:ONTX  Free Report) in a research report sent to investors on Wednesday. The brokerage issued a sell rating on the...

StockNews.com Initiates Coverage on Onconova Therapeutics (NASDAQ:ONTX)

Preclinical data indicate that narazaciclib shows monotherapy and combination anti-tumor activity in ibrutinib-sensitive and resistant cells and xenograft models NEWTOWN, Pa., Nov. 02, 2023 (GLOBE...

Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL

Dr. Victor Moyo named Chief Medical OfficerMeena Arora joins as Vice President Global Medical Affairs and R&D NEWTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ...

Onconova Expands Leadership Team with Two Key Appointments

Data for Mantle cell lymphoma (MCL) presented in Ireland on Oct. 7, 2023Additional studies support broad potential, especially in cyclin-dependent cancers NEWTOWN, Pa., Oct. 19, 2023 (GLOBE...

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

Watchers	45,811
52-Wk Low	$0.5509
52-Wk High	$1.49

Market Cap	$13.67M
Volume (M)	109,543.00
52-Wk High	$1.49
52-Wk Low	$0.5509

ONTX Onconova Therapeutics Inc

About

Feed

News

Earnings

Fundamentals